NCT04755673View on ClinicalTrials.gov

Atrantil for Intestinal Bacterial Overgrowth

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 18, 2020

Primary Completion Date

September 26, 2022

Study Completion Date

September 27, 2022

Conditions
Irritable Bowel SyndromeBacterial Overgrowth SyndromeSIBO
Interventions
OTHER

Atrantil (Medical Food)

All participants will be given 28 days supply of Atrantil. The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.

Trial Locations (1)

60611

Northwestern Medicine Digestive Health Center, Chicago

All Listed Sponsors
lead

Northwestern University

OTHER

NCT04755673 - Atrantil for Intestinal Bacterial Overgrowth | Biotech Hunter | Biotech Hunter